Simeprevir and Sofosbuvir Combination Treatment in a Patient with HCV Cirrhosis and HbS Beta 0-Thalassemia: Efficacy and Safety despite Baseline Hyperbilirubinemia
Hyperbilirubinemia is an adverse reaction of simeprevir (SMV). The majority of these patients were taking concurrent ribavirin presenting elevated unconjugated hyperbilirubinemia due to hemolysis. However, cases of hepatic failure with elevated bilirubin level have also been reported in patients wit...
Saved in:
Main Authors: | Nikolaos Papadopoulos, Melanie Deutsch, Athanasios Georgalas, Helias Poulakidas, Lazaros Karnesis |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2016-01-01
|
Series: | Case Reports in Hematology |
Online Access: | http://dx.doi.org/10.1155/2016/7635128 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
HbS-Sicilian (δβ)0-Thalassemia: A Rare Variant of Sickle Cell
by: Grace Onimoe, et al.
Published: (2017-01-01) -
The Properties of Red Blood Cells from Patients Heterozygous for HbS and HbC (HbSC Genotype)
by: A. Hannemann, et al.
Published: (2011-01-01) -
Successful Treatment of Hepatitis C with Simeprevir, Sofosbuvir, and Ribavirin in an HIV Coinfected Liver Transplant Patient with Advanced Chronic Kidney Disease
by: Anna Maruyama, et al.
Published: (2016-01-01) -
Base editing HbS to HbG-Makassar improves hemoglobin function supporting its use in sickle cell disease
by: Zachary Kostamo, et al.
Published: (2025-02-01) -
Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir
by: Ali Nada, et al.
Published: (2020-01-01)